RU2019128674A - IMMUNOGENIC COMPOSITION FOR IMMUNE SYSTEM MODULATION AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS IN SUBJECT - Google Patents

IMMUNOGENIC COMPOSITION FOR IMMUNE SYSTEM MODULATION AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS IN SUBJECT Download PDF

Info

Publication number
RU2019128674A
RU2019128674A RU2019128674A RU2019128674A RU2019128674A RU 2019128674 A RU2019128674 A RU 2019128674A RU 2019128674 A RU2019128674 A RU 2019128674A RU 2019128674 A RU2019128674 A RU 2019128674A RU 2019128674 A RU2019128674 A RU 2019128674A
Authority
RU
Russia
Prior art keywords
molecular patterns
antigenic agents
spp
agents
patterns associated
Prior art date
Application number
RU2019128674A
Other languages
Russian (ru)
Other versions
RU2019128674A3 (en
Inventor
Александр Эдуардо НОВИЛЛ
Original Assignee
Александр Эдуардо НОВИЛЛ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/431,329 external-priority patent/US10213504B2/en
Application filed by Александр Эдуардо НОВИЛЛ filed Critical Александр Эдуардо НОВИЛЛ
Publication of RU2019128674A publication Critical patent/RU2019128674A/en
Publication of RU2019128674A3 publication Critical patent/RU2019128674A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (7)

1. Фармацевтический продукт, содержащий один или более антибиотиков и одну или более иммуногенных композиций с IRS для модуляции иммунной системы, содержащих терапевтически эффективное количество трех или более синтетических антигенных агентов или естественных антигенных агентов, или их фракций и комбинаций, содержащих ассоциированные с патогенами молекулярные паттерны (РАМР) и/или ассоциированные с опасностью молекулярные паттерны (DAMP), выбранные по меньшей мере из двух групп, состоящих из: (А) антигенных агентов с молекулярными паттернами, ассоциированными с бактериями, (В) антигенных агентов с молекулярными паттернами, ассоциированными с вирусами, (С) антигенных агентов с молекулярными паттернами, ассоциированными с грибами и дрожжами, (D) антигенных агентов с молекулярными паттернами, ассоциированными с простейшими, (Е) антигенных агентов с молекулярными паттернами, ассоциированными с гельминтами; и (F) антигенных агентов с молекулярными паттернами, ассоциированными с прионами; и один или более физиологически приемлемых носителей, вспомогательных веществ, разбавителей или растворителей.1. A pharmaceutical product containing one or more antibiotics and one or more immunogenic compositions with IRS for modulating the immune system, containing a therapeutically effective amount of three or more synthetic antigenic agents or natural antigenic agents, or their fractions and combinations containing molecular patterns associated with pathogens (PAMP) and / or hazard-associated molecular patterns (DAMP), selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with helminths; and (F) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable carriers, excipients, diluents or solvents. 2. Фармацевтический продукт по п. 1, отличающийся тем, что указанные антибиотики выбраны из следующих классов: производные аминокислот, аминогликозиды, ауреоловые кислоты, азиридины, ансамицины, бензоиды, бензимидазолы, карбапенемы, цефалоспорин, кумариновые гликозиды, производные простого дифенилового эфира, эпиполитиодиоксопиперазины, производные жирных кислот, глюкозамин, гликопептиды, имидазолы, производные индола, липопептиды макролактамы, макролиды, нуклеозиды. пенициллины и цефалоспорины (бета-лактамы), пептиды, пептидил-нуклеозиды, фениколы, полиены, простые полиэфиры, пиридины и пиримидины, хинолоны и фторхинолоны, статины, стероиды, сульфаниламиды, таксоиды и тетрациклины.2. A pharmaceutical product according to claim 1, characterized in that said antibiotics are selected from the following classes: amino acid derivatives, aminoglycosides, aureolic acids, aziridines, ansamycins, benzoids, benzimidazoles, carbapenems, cephalosporin, coumarin glycosides, diphenyl ether derivatives, epipiperazines derivatives of fatty acids, glucosamine, glycopeptides, imidazoles, indole derivatives, macrolactam lipopeptides, macrolides, nucleosides. penicillins and cephalosporins (beta-lactams), peptides, peptidyl nucleosides, fenicols, polyenes, polyethers, pyridines and pyrimidines, quinolones and fluoroquinolones, statins, steroids, sulfonamides, taxoids and tetracyclines. 3. Фармацевтический продукт по п. 2 отличающийся тем, что указанные антибиотики выбраны из следующих классов: ансамицины, пенициллины, цефалоспорины, карбапенемы и липопептиды.3. A pharmaceutical product according to claim 2, wherein said antibiotics are selected from the following classes: ansamycins, penicillins, cephalosporins, carbapenems and lipopeptides. 4. Фармацевтический продукт по п. 1, отличающийся тем, что указанные антигенные агенты выбраны из по меньшей мере четырех групп (А), (В), (С), (D), (Е) и (F).4. A pharmaceutical product according to claim 1, wherein said antigenic agents are selected from at least four groups (A), (B), (C), (D), (E) and (F). 5. Фармацевтический продукт по п. 1, содержащий от 4 до 20 антигенных агентов, выбранных из группы, состоящей из антигенных агентов, происходящих из: дорназы, леведурина, оидиомицина, очищенного производного белка бациллы Коха (PPD), прионов, стрептокиназ, токсоида Streptococcus, дифтерийного токсоида, столбнячного токсоида, оригинального туберкулина Коха, инактивированных лизатов Ascaris lumbricoides, Aspergillus spp., Aspergillus flavus, Aspergillus fumigatus, Aspergillus terreus, Candida albicans, Candida glabrata, Candida parapsilosis, Chlamydia spp., Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Cryptosporidium spp., Dermatophytes, Entamoeba hystolitica, Enterobius vermicularis, Enterococcus faecalis, Epidermophyton floccosum, Escherichia coli, Giardia lamblia, Haemophilus influenzae, Microsporum canis, Mycobacterium spp., Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis, Neisseria gonorrhoeae, папилломавируса человека, полиовируса, Proteus spp., Proteus mirabilis, Proteus penerii, Proteus vulgaris, Salmonella spp., Salmonella bongori, Salmonella enterica, Serratia spp., Serratia liquefaciens, Serratia marcencens, Shigella spp., Shigella flexneri, Shigella sonnei, Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Strongyloides stercoralis, Streptococcus spp., Streptococcus bovis, Streptococcus viridans, Streptococcus equinus, Streptococcus pneumoniae, Streptococcus pyogenes, Toxoplasma gondii, Trichomonas vaginalis, трихофитин, Trichophyton spp., Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, вируса желтой лихорадки, вируса гепатита В, вируса краснухи, вируса ветряной оспы, вируса натуральной оспы, вируса эпидемического паротита, вируса кори, вируса герпеса и вируса осповакцины, или синтетических аналогов, представляющих ассоциированные с патогенами молекулярные паттерны (РАМР) и/или ассоциированные с опасностью молекулярные паттерны (DAMP), ассоциированные с указанными антигенными агентами.5. A pharmaceutical product according to claim 1, containing from 4 to 20 antigenic agents selected from the group consisting of antigenic agents derived from: dornase, levedurine, oidiomycin, purified bacillus Koch protein derivative (PPD), prions, streptokinases, Streptococcus toxoid , diphtheria toxoid, tetanus toxoid, original Koch tuberculin, inactivated lysates from Ascaris lumbricoides, Aspergillus spp., Aspergillus flavus, Aspergillus fumigatus, Aspergillus terreus, Candida albicans, Candida glabrata. , Cryptosporidium spp., Dermatophytes, Entamoeba hystolitica, Enterobius vermicularis, Enterococcus faecalis, Epidermophyton floccosum, Escherichia coli, Giardia lamblia, Haemophilus influenzae, Microsporum canis, Mycobacterium spp. poliovirus, Proteus spp., Proteus mirabilis, Proteus penerii, Proteus vulgaris, Salmonella spp., Salmonella bongori, Salmonella enterica, Serratia spp., Serratia liquefaciens, Serratia marcencens, Shigella spp., Shigella flexneri, Shigella sonnei, Staphylococaplous spp. epidermidis, Strongyloides stercoralis, Streptococcus spp., Streptococcus bovis, Streptococcus viridans, Streptococcus equinus, Streptococcus pneumoniae, Streptococcus pyogenes, Toxoplasma gondii, Trichomonas vaginalis, trichophytin, Trichophyton spp. hepatitis B, rubella virus, varicella-zoster virus, variola virus, mumps virus, measles virus, herpes virus and vaccinia virus, or synthetic analogs representing pathogen-associated molecular patterns (PAMP) and / or hazard-associated molecular patterns (DAMP ) associated with the indicated ant genetic agents. 6. Способ лечения сепсиса и полирезистентной бактериальной инфекции у человека или животного, включающий введение указанному человеку или животному эффективного количества одного или более антибиотиков и одной или более иммуногенных композиций с IRS, содержащих терапевтически эффективное количество трех или более синтетических антигенных агентов или естественных антигенных агентов, или их фракций и комбинаций, содержащих ассоциированные с патогенами молекулярные паттерны (РАМР) и/или ассоциированные с опасностью молекулярные паттерны (DAMP), выбранные по меньшей мере из двух групп, состоящих из: (А) антигенных агентов с молекулярными паттернами, ассоциированными с бактериями, (В) антигенных агентов с молекулярными паттернами, ассоциированными с вирусами, (С) антигенных агентов с молекулярными паттернами, ассоциированными с грибами и дрожжами, (D) антигенных агентов с молекулярными паттернами, ассоциированными с простейшими, (Е) антигенных агентов с молекулярными паттернами, ассоциированными с гельминтами; и (F) антигенных агентов с молекулярными паттернами, ассоциированными с прионами; и один или более физиологически приемлемых носителей, вспомогательных веществ, разбавителей или растворителей.6. A method of treating sepsis and multidrug-resistant bacterial infection in a human or animal, comprising administering to said human or animal an effective amount of one or more antibiotics and one or more immunogenic compositions with IRS containing a therapeutically effective amount of three or more synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof containing pathogen-associated molecular patterns (PAMP) and / or hazard-associated molecular patterns (DAMP) selected from at least two groups consisting of: (A) antigenic agents with bacterial-associated molecular patterns , (B) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeast, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns , associate data with helminths; and (F) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable carriers, excipients, diluents or solvents. 7. Способ модуляции ответа иммунной системы у человека или животного, у которого имеется бактериальная инфекция, включающий введение указанному человеку или животному эффективного количества одной или более иммуногенных композиций с IRS, содержащих терапевтически эффективное количество трех или более синтетических антигенных агентов или естественных антигенных агентов, или их фракций и комбинаций, содержащих ассоциированные с патогенами молекулярные паттерны (РАМР) и/или ассоциированные с опасностью молекулярные паттерны (DAMP), выбранные по меньшей мере из двух групп, состоящих из: (А) антигенных агентов с молекулярными паттернами, ассоциированными с бактериями, (В) антигенных агентов с молекулярными паттернами, ассоциированными с вирусами, (С) антигенных агентов с молекулярными паттернами, ассоциированными с грибами и дрожжами, (D) антигенных агентов с молекулярными паттернами, ассоциированными с простейшими, (Е) антигенных агентов с молекулярными паттернами, ассоциированными с гельминтами; и (F) антигенных агентов с молекулярными паттернами, ассоциированными с прионами; и один или более физиологически приемлемых носителей, вспомогательных веществ, разбавителей или растворителей.7. A method of modulating an immune system response in a human or animal that has a bacterial infection, comprising administering to said human or animal an effective amount of one or more immunogenic compositions with IRS containing a therapeutically effective amount of three or more synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof containing pathogen-associated molecular patterns (PAMP) and / or hazard-associated molecular patterns (DAMP), selected from at least two groups, consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeast, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns, associated with helm intami; and (F) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable carriers, excipients, diluents or solvents.
RU2019128674A 2017-02-13 2018-02-15 IMMUNOGENIC COMPOSITION FOR IMMUNE SYSTEM MODULATION AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS IN SUBJECT RU2019128674A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/431,329 US10213504B2 (en) 2011-03-18 2017-02-13 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
US15/431,329 2017-02-13
PCT/BR2018/000004 WO2018145180A1 (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject

Publications (2)

Publication Number Publication Date
RU2019128674A true RU2019128674A (en) 2021-03-16
RU2019128674A3 RU2019128674A3 (en) 2021-06-18

Family

ID=63106848

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019128674A RU2019128674A (en) 2017-02-13 2018-02-15 IMMUNOGENIC COMPOSITION FOR IMMUNE SYSTEM MODULATION AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS IN SUBJECT

Country Status (10)

Country Link
EP (1) EP3579868A4 (en)
JP (1) JP2020507629A (en)
KR (1) KR20190139209A (en)
CN (1) CN110709099B (en)
AU (1) AU2018217441A1 (en)
BR (1) BR112019016670A2 (en)
IL (1) IL268626B2 (en)
MX (1) MX2019009689A (en)
RU (1) RU2019128674A (en)
WO (1) WO2018145180A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096270A1 (en) * 2003-04-30 2004-11-11 Medi Service S.R.L. Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
WO2005077408A2 (en) * 2004-02-06 2005-08-25 Vaxinnate Corporation Compositions of pamps and listeria monocytogenes and methods of use
EP2064230A2 (en) * 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
EP2303236A4 (en) * 2008-07-01 2012-09-26 Univ Emory Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
SG177533A1 (en) * 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
MX2012000734A (en) * 2009-07-16 2012-01-27 Novartis Ag Detoxified escherichia coli immunogens.
US8980279B2 (en) * 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
BRPI1100857A2 (en) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill immunomodulatory agent and combinations thereof, their use and immunotherapeutic method for real time recontextualization, reprogramming and rebuilding of the immune system

Also Published As

Publication number Publication date
EP3579868A1 (en) 2019-12-18
WO2018145180A1 (en) 2018-08-16
CN110709099B (en) 2024-03-29
KR20190139209A (en) 2019-12-17
CN110709099A (en) 2020-01-17
AU2018217441A1 (en) 2019-10-03
BR112019016670A2 (en) 2020-04-14
IL268626B1 (en) 2023-12-01
IL268626A (en) 2019-10-31
MX2019009689A (en) 2019-12-18
IL268626B2 (en) 2024-04-01
JP2020507629A (en) 2020-03-12
EP3579868A4 (en) 2021-01-06
RU2019128674A3 (en) 2021-06-18

Similar Documents

Publication Publication Date Title
MY182282A (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
HRP20160276T1 (en) Compositions for immunising against staphylococcus aureus
JP2014139229A5 (en)
HRP20191166T1 (en) Stabilised proteins for immunising against staphylococcus aureus
DK84083D0 (en) PROCEDURE FOR THE PREPARATION OF POLYSACCHARID PROTEIN COMPLEXS FROM BACTERIAL CAPSULES
EA201991065A1 (en) PORK PARVOVIRUS VACCINE
RU2018114480A (en) SALTS AND SOLID FORMS OF MONOBACTAM ANTIBIOTIC
HRP20231044T1 (en) Novel polypeptides and medical uses thereof
BR112019007927A2 (en) polymyxin conjugates? alginate oligomers
NO944786D0 (en) One-flask method for preparing 3-quinolone carboxylic acid derivatives
NO156010B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE, WATER SOLUBLE SALTS OF (+) CATECHIN.
RU2019128674A (en) IMMUNOGENIC COMPOSITION FOR IMMUNE SYSTEM MODULATION AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS IN SUBJECT
CY1111188T1 (en) ANTIBACTERIAL PRODUCERS OF KINOLIN
EA201690859A1 (en) PREVENTION OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS, GLYOPROTEIN VACCINES SYNTHESIZED IN ESCHERICHIA COLI
WO2019032936A8 (en) Lincosamide antibiotics and uses thereof
RU2018116601A (en) Immunogenic Fusion Protein
AU2017208117B2 (en) Freeze-dried formulations of antibacterial protein
MX2019005775A (en) Pharmaceutical parenteral formulation containing carglumic acid.
CA3021005A1 (en) Method of long-term preservation of chemical and biological species using sugar glasses
WO2016057630A3 (en) Method of treating infections using siloxane derivatives
RU2018137673A (en) ANTIGENS AND ANTIGEN COMBINATIONS PSEUDOMONAS
CY1110706T1 (en) ANTIBACTERIAL PRODUCTS OF KINOLIN
RU2009128327A (en) LYOPHILIZED INJECTED PHARMACEUTICAL COMPOSITION OF VINCA SEMI-SYNTHETIC ALKALOIDS AND CARBOHYDRATE, STABLE AT ROOM TEMPERATURE
WO2016028002A1 (en) Process for preparing ertapenem-containing lyophilized formulation
SE8007403L (en) NEW 1-OXADETHYACTHPHALOSPORINE DERIVATIVES AND PREPARATION THEREOF